This randomised, double-blind, placebo-controlled trial (n=50) tested low-dose sublingual buprenorphine after ketamine in adults with major depressive disorder and suicidal thoughts. Buprenorphine led to a greater and longer-lasting reduction in suicidal ideation than placebo, while depression scores were similar and no serious treatment-related side effects occurred.
- Published
- Journal
- American Journal of Psychiatry
- Authors
- Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., Schatzberg, A. F.